STOCK TITAN

Establishment Labs to Announce Third Quarter 2023 Financial Results on November 7

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Flora, the magnet-free and MR Conditional tissue expander, has been cleared for the U.S. market. Establishment Labs Holdings Inc. plans to announce its financial results for Q3 2023 on November 7, 2023, and will host a conference call to discuss those results.
Positive
  • Flora, the magnet-free and MR Conditional tissue expander, has been cleared for the U.S. market.
  • Establishment Labs Holdings Inc. plans to announce its financial results for Q3 2023 on November 7, 2023.
Negative
  • None.

Flora is the only magnet-free and MR Conditional tissue expander cleared for the U.S. market.

NEW YORK--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended Semptember 30, 2023, after the market closes on Tuesday, November 7, 2023, and will host a conference call at 4:30 pm ET that day to discuss those results.

To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or (201) 689-8037 (International) and use conference ID number 13740398. The call will also be available via live or archived webcast in the “Investor Relations” section of the Establishment Labs website at www.establishmentlabs.com

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness through the power of science, engineering, and technology. The Company offers a portfolio of Femtech solutions for breast health, breast aesthetics and breast reconstruction. The over three million Motiva® devices Establishment Labs has delivered to plastic and reconstructive surgeons since 2010 have created a new standard for safety and patient satisfaction in the over 85 countries in which they are available. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and it is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MR conditional. Mia Femtech™, Establishment Lab’s unique minimally invasive experience for breast harmony, is the Company’s most recent breakthrough innovation. These solutions are supported by over 200 patent applications in 25 separate patent families worldwide and over 50 scientific studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. In 2018, the Company received an investigational device exemption (IDE) from the FDA for Motiva Implants® and began a clinical trial to support regulatory approval in the United States. Please visit our website for additional information at www.establishmentlabs.com.

Establishment Labs' Motiva silicone gel-filled implants are currently not approved for commercial distribution in the United States. The Company’s implants are undergoing PMA clinical investigation pursuant to U.S. FDA regulations for investigational medical devices.

Investor/Media Contact:

Raj Denhoy

415-828-1044

rdenhoy@establishmentlabs.com

Source: Establishment Labs Holdings Inc.

FAQ

When will Establishment Labs Holdings Inc. announce its financial results for Q3 2023?

Establishment Labs Holdings Inc. will announce its financial results for Q3 2023 on November 7, 2023.

What is Flora?

Flora is a magnet-free and MR Conditional tissue expander that has been cleared for the U.S. market.

Establishment Labs Holdings Inc.

NASDAQ:ESTA

ESTA Rankings

ESTA Latest News

ESTA Stock Data

1.56B
16.31M
12.45%
75.8%
18.1%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
ALAJUELA

About ESTA

establishment labs is a global, privately held, high-tech medical device and aesthetics company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants. with more than 30 years of advanced breast implant manufacturing experience, building quality breast implants has always been a natural outcome for establishment labs’ founders and top executives. as a result, motiva implants® has established a level of product innovation that always results in safety. and while we respect our past, we ́re more focused on the present and the future, one that ́s innovative, safe and progressive. we believe that these goals can be achieved by incorporating the current needs and preferences of plastic surgeons and patients into our product design.